PMC7695685_01
PET CT scan of the chest-mediastinal window. Neoplastic aorto-pulmonary, mediastinal para aortic and left paravertebral lymph nodes. (A) Baseline disease. (B) Complete disease response after 12 weeks of therapy with osimertinib.
OTT-13-12027-g0001.jpg
PMC7695685_01_OTT-13-12027-g0001.jpg
f0001
During follow-up, a Computed Tomography (CT) scan performed in November 2019 and a Positron Emission Tomography CT (PET-CT) scan in December 2019 showed disease recurrence in multiple small lung nodes and mediastinal para aortic, aorto-pulmonary and left paravertebral lymph nodes (Figures 1A and 2A). On the 21st of April 2020, a restaging PET CT scan demonstrated a disease complete response to osimertinib (Figures 1B and 2B).
Chest CT scan. (A) Baseline disease in multiple small lung nodes. (B) Complete disease response after 12 weeks of therapy with osimertinib.
OTT-13-12027-g0002.jpg
PMC7695685_01_OTT-13-12027-g0002.jpg
f0002
During follow-up, a Computed Tomography (CT) scan performed in November 2019 and a Positron Emission Tomography CT (PET-CT) scan in December 2019 showed disease recurrence in multiple small lung nodes and mediastinal para aortic, aorto-pulmonary and left paravertebral lymph nodes (Figures 1A and 2A). On the 21st of April 2020, a restaging PET CT scan demonstrated a disease complete response to osimertinib (Figures 1B and 2B).